Dr. McCollum on Drug Sequences for Patients With CRC

A. David McCollum, MD
Published: Friday, Nov 17, 2017



A. David McCollum, MD, Baylor-Sammons Cancer Center, discusses drug sequences for patients with colorectal cancer (CRC).

Patients with CRC are generally treated with a biologic drug in combination with chemotherapy. Over time, the intensity of the chemotherapy is modified or lightened to try to maintain benefit for as long as possible.

There is still debate about which maintenance therapy is best for frontline treatment, as well as what constitutes as enough progression for a patient to need second-line therapy, says McCollum.


A. David McCollum, MD, Baylor-Sammons Cancer Center, discusses drug sequences for patients with colorectal cancer (CRC).

Patients with CRC are generally treated with a biologic drug in combination with chemotherapy. Over time, the intensity of the chemotherapy is modified or lightened to try to maintain benefit for as long as possible.

There is still debate about which maintenance therapy is best for frontline treatment, as well as what constitutes as enough progression for a patient to need second-line therapy, says McCollum.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Working Group to Optimize Outcomes in EGFR-mutated Lung Cancers: Evolving Concepts for Nurses to Facilitate and Improve Patient CareJun 30, 20181.5
Oncology Briefings™: Overcoming Chronic Iron Overload in Pediatric AML and MDSJun 30, 20181.0
Publication Bottom Border
Border Publication
x